Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2011

Open Access 01-12-2011 | Research

Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC)

Authors: Meiju Ji, Yong Zhang, Bingyin Shi, Peng Hou

Published in: Diagnostic Pathology | Issue 1/2011

Login to get access

Abstract

Background

Lung cancer is a major cause of death worldwide. Gene promoter methylation is a major inactivation mechanism of tumor-related genes, some of which can be served as a biomarker for early diagnosis and prognosis evaluation of lung cancer.

Methods

We determined the promoter methylation of 6 genes using quantitative methylation-specific PCR (Q-MSP) technique in 96 clinically well-characterized non-small cell lung cancer (NSCLC).

Results

Highly frequent promoter methylation was found in NSCLC. With 100% diagnostic specificity, high sensitivity, ranging from 44.9 to 84.1%, was found for each of the 6 genes. Our data also showed that promoter methylation was closely associated with histologic type. Most of genes were more frequently methylated in squamous cell carcinomas (SCC) compared to adenocarcinomas (ADC). Moreover, promoter methylation significantly increased the risk of pleural indentation in NSCLC.

Conclusion

Our findings provided evidences that multiple genes were aberrantly methylated in lung tumorigenesis, and demonstrated the promoter methylation was closely associated with clinicopathologic characteristics of NSCLC. More importantly, we first revealed promoter methylation may be served as a potentially increased risk factor for pleural indentation of NSCLC patients.
Appendix
Available only for authorised users
Literature
1.
Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001, 37 (Suppl 8): S4-66.PubMed
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-49. 10.3322/caac.20006.CrossRefPubMed
3.
Song F, He M, Li H, Qian B, Wei Q, Zhang W, Chen K, Hao X: A cancer incidence survey in Tianjin: the third largest city in China-between 1981 and 2000. Cancer Causes Control. 2008, 19: 443-50. 10.1007/s10552-007-9105-6.CrossRefPubMed
4.
Yang L, Parkin DM, Li LD, Chen YD, Bray F: Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer. 2004, 90: 2157-66.PubMedCentralPubMed
5.
6.
Schwartz AG, Prysak GM, Bock CH, Cote ML: The molecular epidemiology of lung cancer. Carcinogenesis. 2007, 28: 507-18.CrossRefPubMed
7.
Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, et al.: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008, 452: 633-7. 10.1038/nature06885.CrossRefPubMed
8.
Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsäter A, Flex A, Aben KK, de Vegt F, et al.: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008, 452: 638-42. 10.1038/nature06846.PubMedCentralCrossRefPubMed
9.
Risch A, Plass C: Lung cancer epigenetics and genetics. Int J Cancer. 2008, 123: 1-7. 10.1002/ijc.23605.CrossRefPubMed
10.
Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002, 3: 415-28.CrossRefPubMed
11.
Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007, 8: 286-98. 10.1038/nrg2005.CrossRefPubMed
12.
13.
Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61: 3225-9.PubMed
14.
Hou P, Ji M, Xing M: Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008, 113: 2440-7. 10.1002/cncr.23869.CrossRefPubMed
15.
Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, Condouris S, Tallini G, Westra WH, Umbricht CB, Zeiger MA, Califano JA, Vasko V, Xing M: Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006, 119: 2322-9. 10.1002/ijc.22110.CrossRefPubMed
16.
Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, Caballero OL, Westra WH, Sidransky D, Hoque MO: Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2008, 17: 2786-94. 10.1158/1055-9965.EPI-08-0192.PubMedCentralCrossRefPubMed
17.
Paixão VA, Vidal DO, Caballero OL, Vettore AL, Tone LG, Ribeiro KB, Lopes LF: Hypermethylation of CpG island in the promoter region of CALCA in acute lymphoblastic leukemia with central nervous system (CNS) infiltration correlates with poorer prognosis. Leuk Res. 2006, 30: 891-4. 10.1016/j.leukres.2005.11.016.CrossRefPubMed
18.
Berx G, van Roy F: Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009, 1: a003129-10.1101/cshperspect.a003129.PubMedCentralCrossRefPubMed
19.
Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA, Blin N: Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Cancer Genet Cytogenet. 2010, 199: 96-100. 10.1016/j.cancergencyto.2010.02.007.CrossRefPubMed
20.
Christoffels VM, Keijser AG, Houweling AC, Clout DE, Moorman AF: Patterning the embryonic heart: identification of five mouse Iroquois homeobox genes in the developing heart. Dev Biol. 2000, 224: 263-74. 10.1006/dbio.2000.9801.CrossRefPubMed
21.
Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z, Riggs AD, Pfeifer GP: High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA. 2008, 105: 252-7. 10.1073/pnas.0710735105.PubMedCentralCrossRefPubMed
22.
Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999, 59: 798-802.PubMed
23.
Robson EJ, He SJ, Eccles MR: A PANorama of PAX genes in cancer and development. Nat Rev Cancer. 2006, 6: 52-62. 10.1038/nrc1778.CrossRefPubMed
24.
Hellwinkel OJ, Kedia M, Isbarn H, Budäus L, Friedrich MG: Methylation of the TPEF-and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours. BJU Int. 2008, 101: 753-7. 10.1111/j.1464-410X.2007.07322.x.CrossRefPubMed
25.
Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998, 95: 11891-6. 10.1073/pnas.95.20.11891.PubMedCentralCrossRefPubMed
26.
Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M: Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol. 2000, 18: 3221-9.PubMed
27.
Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, Kelsey KT: p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001, 61: 3419-24.PubMed
28.
Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 2003, 103: 153-60. 10.1002/ijc.10787.CrossRefPubMed
29.
Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J, Park J: Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 2003, 63: 3743-6.PubMed
30.
Toyooka S, Suzuki M, Tsuda T, Toyooka KO, Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N, Minna JD, Gazdar AF: Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer. 2004, 110: 462-4. 10.1002/ijc.20125.CrossRefPubMed
31.
Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH: Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis. 2004, 25: 2165-71. 10.1093/carcin/bgh217.CrossRefPubMed
32.
de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC: Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer. Lung Cancer. 2005, 50: 199-209. 10.1016/j.lungcan.2005.05.019.CrossRefPubMed
33.
Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, Yang SC, Sidransky D: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res. 2003, 9: 1370-5.PubMed
34.
Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X: Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006, 12: 7329-38. 10.1158/1078-0432.CCR-06-0894.CrossRefPubMed
35.
Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T: Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer. 2007, 58: 131-8. 10.1016/j.lungcan.2007.05.011.CrossRefPubMed
36.
Hawes SE, Stern JE, Feng Q, Wiens LW, Rasey JS, Lu H, Kiviat NB, Vesselle H: DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer. 2010, 69: 172-9. 10.1016/j.lungcan.2009.11.002.PubMedCentralCrossRefPubMed
37.
Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K: The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer. 2006, 106: 2190-9. 10.1002/cncr.21870.CrossRefPubMed
38.
Kim DS, Kim MJ, Lee JY, Kim YZ, Kim EJ, Park JY: Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer. 2007, 110: 2785-92. 10.1002/cncr.23113.CrossRefPubMed
39.
Vaissiere T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, Ferro G, Paliwal A, Hainaut P, Brennan P, Tost J, Boffetta P, Herceg Z: Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009, 69: 243-52. 10.1158/0008-5472.CAN-08-2489.PubMedCentralCrossRefPubMed
40.
Issa JP, Baylin SB, Belinsky SA: Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 1996, 56: 3655-8.PubMed
41.
Moore LE, Huang WY, Chung J, Hayes RB: Epidemiologic considerations to assess altered DNA methylation from environmental exposures in cancer. Ann N Y Acad Sci. 2003, 983: 181-96. 10.1111/j.1749-6632.2003.tb05973.x.CrossRefPubMed
42.
Vuillemenot BR, Pulling LC, Palmisano WA, Hutt JA, Belinsky SA: Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. Carcinogenesis. 2004, 25: 623-9.CrossRefPubMed
43.
Gilliland FD, Harms HJ, Crowell RE, Li YF, Willink R, Belinsky SA: Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum. Cancer Res. 2002, 62: 2248-52.PubMed
44.
Shapiro R, Wilson GL, Yesner R, Shuman H: A useful roentgen sign in the diagnosis of localized bronchioloalveolar carcinoma. Am J Roentgenol Radium Ther Nucl Med. 1972, 114: 516-24.CrossRefPubMed
45.
Kuhlman JE, Fishman EK, Kuhajda FP, Meziane MM, Khouri NF, Zerhouni EA, Siegelman SS: Solitary bronchioloalveolar carcinoma: CT criteria. Radiology. 1988, 167: 379-82.CrossRefPubMed
46.
Li M, Ito H, Wada H, Tanaka F: Pit-fall sign on computed tomography predicts pleural involvement and poor prognosis in non-small cell lung cancer. Lung Cancer. 2004, 46: 349-55. 10.1016/j.lungcan.2004.05.017.CrossRefPubMed
47.
Murayama S, Murakami J, Yoshimitsu K, Torii Y, Ishida T, Masuda K: CT diagnosis of pleural dissemination without pleural effusion in primary lung cancer. Radiat Med. 1996, 14: 117-9.PubMed
Metadata
Title
Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC)
Authors
Meiju Ji
Yong Zhang
Bingyin Shi
Peng Hou
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2011
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-6-48

Other articles of this Issue 1/2011

Diagnostic Pathology 1/2011 Go to the issue

Case Report

Primary angiosarcoma of the ovary with prominent fibrosis of the ovarian stroma. Case report of an 81-year old patient

Case Report

Peritoneal keratin granuloma associated with endometrioid adenocarcinoma of the uterine corpus

Research

Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: A historical prospective study

Research

Molecular analysis of mucopolysaccharidosis type I in Tunisia: identification of novel mutation and eight Novel polymorphisms

Case Report

Giant ectopic liver, hepatocellular carcinoma and pachydermia-a rare genetic syndrome?

Methodology

An inexpensive method of small paraffin tissue microarrays using mechanical pencil tips